Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica

Arthritis and Rheumatology

Volumn 66, Issue 7, 2014, Pages 1927-1938

  Van Der Geest, Kornelis S M ^a   Abdulahad, Wayel H ^a   Chalan, Paulina ^a   Rutgers, Abraham ^a   Horst, Gerda ^a   Huitema, Minke G ^a   Roffel, Mirjam P ^a   Roozendaal, Caroline ^a   Kluin, Philip M ^a   Bos, Nicolaas A ^a   Boots, Annemieke M H ^a   Brouwer, Elisabeth ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; C REACTIVE PROTEIN; INTERLEUKIN 10; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; GIANT CELL ARTERITIS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; TEMPORAL ARTERY;

ADRENAL CORTEX HORMONES; AGED; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; B-LYMPHOCYTES, REGULATORY; CELL DIFFERENTIATION; FEMALE; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; HOMEOSTASIS; HUMANS; INTERLEUKIN-6; LYMPHOCYTE SUBSETS; MALE; POLYMYALGIA RHEUMATICA; PROSPECTIVE STUDIES;

EID: 84903458001     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38625     Document Type: Article

References (48)

1. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61: 1454-61.
2. Salvarani C, Cantini F, Hunder GG,. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-45.
3. Nesher G, Sonnenblick M, Friedlander Y,. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283-6.
4. Weyand CM, Goronzy JJ,. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013; 9: 731-40.
5. Meliconi R, Pulsatelli L, Uguccioni M, Salvarani C, Macchioni P, Melchiorri C, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica: quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 1996; 39: 1199-207.
6. Cid MC, Campo E, Ercilla G, Palacin A, Vilaseca J, Villalta J, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis: influence of corticosteroid treatment. Arthritis Rheum 1989; 32: 884-93.
7. Banks PM, Cohen MD, Ginsburg WW, Hunder GG,. Immunohistologic and cytochemical studies of temporal arteritis. Arthritis Rheum 1983; 26: 1201-7.
8. Belilos E, Maddox J, Kowalewski RM, Kowalewska J, Turi GK, Nochomovitz LE, et al. Temporal small-vessel inflammation in patients with giant cell arteritis: clinical course and preliminary immunohistopathologic characterization. J Rheumatol 2011; 38: 331-8.
9. Andersson R, Jonsson R, Tarkowski A, Bengtsson BA, Malmvall BE,. T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis. Ann Rheum Dis 1987; 46: 915-23.
10. Martinez-Taboada V, Brack A, Hunder GG, Goronzy JJ, Weyand CM,. The inflammatory infiltrate in giant cell arteritis selects against B lymphocytes. J Rheumatol 1996; 23: 1011-4.
11. Regent A, Dib H, Ly KH, Agard C, Tamby MC, Tamas N, et al. Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. Arthritis Res Ther 2011; 13: R107.
12. Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, Gonzalez-Gay MA, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012; 71: 943-7.
13. Schmits R, Kubuschok B, Schuster S, Preuss KD, Pfreundschuh M,. Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol 2002; 127: 379-85.
14. Thurner L, Preuss KD, Fadle N, Regitz E, Klemm P, Zaks M, et al. Progranulin antibodies in autoimmune diseases. J Autoimmun 2013; 42: 29-38.
15. Regent A, Ly KH, Blet A, Agard C, Puechal X, Tamas N, et al. Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. Ann Rheum Dis 2013; 72: 1269-70.
16. Liang GC, Simkin PA, Mannik M,. Immunoglobulins in temporal arteries: an immunofluorescent study. Ann Intern Med 1974; 81: 19-24.
17. Park JR, Hazleman BL,. Immunological and histological study of temporal arteries. Ann Rheum Dis 1978; 37: 238-43.
18. Bhatia A, Ell PJ, Edwards JC,. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005; 64: 1099-100.
19. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
20. Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012; 71: 75-9.
21. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32: 129-40.
22. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530-41.
23. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475-82.
24. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209: 1001-10.
25. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
26. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT,. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80.
27. Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011; 63: 1116-23.
28. Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I,. Advances in human B cell phenotypic profiling. Front Immunol 2012; 3: 302.
29. Driessen GJ, van Zelm MC, van Hagen PM, Hartwig NG, Trip M, Warris A, et al. B-cell replication history and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable immunodeficiency. Blood 2011; 118: 6814-23.
30. Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 2012; 188: 497-503.
31. Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG, Meijer JM, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 2013; 72: 146-8.
32. Chang SK, Arendt BK, Darce JR, Wu X, Jelinek DF,. A role for BLyS in the activation of innate immune cells. Blood 2006; 108: 2687-94.
33. Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. Arthritis Res Ther 2011; 13: R170.
34. + T cell immunity. Nat Rev Immunol 2010; 10: 236-47.
35. Holub M, Kluckova Z, Helcl M, Prihodov J, Rokyta R, Beran O,. Lymphocyte subset numbers depend on the bacterial origin of sepsis. Clin Microbiol Infect 2003; 9: 202-11.
36. Fantin B, Joly V, Elbim C, Golmard JL, Gougerot-Pocidalo MA, Yeni P, et al. Lymphocyte subset counts during the course of community-acquired pneumonia: evolution according to age, human immunodeficiency virus status, and etiologic microorganisms. Clin Infect Dis 1996; 22: 1096-8.
37. Lill-Elghanian D, Schwartz K, King L, Fraker P,. Glucocorticoid-induced apoptosis in early B cells from human bone marrow. Exp Biol Med (Maywood) 2002; 227: 763-70.
38. Cupps TR, Fauci AS,. Corticosteroid-mediated immunoregulation in man. Immunol Rev 1982; 65: 133-55.
39. + plasma cells. Haematologica 2010; 95: 1016-20.
40. Cupps TR, Gerrard TL, Falkoff RJ, Whalen G, Fauci AS,. Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest 1985; 75: 754-61.
41. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8: R167.
42. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096-103.
43. Mackay F, Schneider P,. Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491-502.
44. McHeyzer-Williams LJ, McHeyzer-Williams MG,. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23: 487-513.
45. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011; 118: 2150-8.
46. + B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP- but not UNC-93B-deficient patients. Blood 2012; 120: 4992-5001.
47. Wilde B, Thewissen M, Damoiseaux J, Knippenberg S, Hilhorst M, van Paassen P, et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013; 72: 1416-9.
48. Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012; 64: 3788-98.